When was Primmune Therapeutics founded?

Primmune Therapeutics was founded in 2017 and raised its 1st funding round within a year of its incorporation.

Where is Primmune Therapeutics located?

Primmune Therapeutics is headquartered in San Diego, United States.

How many employees does Primmune Therapeutics have?

As of Jun 30, 2026, the latest employee count at Primmune Therapeutics is 9.

Is Primmune Therapeutics a funded company?

Primmune Therapeutics is a funded company, having raised a total of $60M across 8 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Oct 18, 2017.

When was the latest funding round of Primmune Therapeutics?

Primmune Therapeutics' latest funding was a $***** Series B round on Jan 26, 2026, with participation from 3 investors. Its primary sector is Immunotherapy. In United States, the Immunotherapy sector has seen $1.2B in funding in 2026 to date.

Where does Primmune Therapeutics rank among its competitors?

Primmune Therapeutics ranks 14th amongst 337 active competitors, of which 132 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Primmune Therapeutics, which secured $8.6M in Jan, 2026.

Who are the top competitors of Primmune Therapeutics?

Primmune Therapeutics' top competitors include Abcellera Biologics, Agios Pharmaceuticals and TScan Therapeutics. Among them, Primmune Therapeutics secured the most recent funding round in January, 2026.

Primmune Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Primmune Therapeutics is a series B company based in San Diego (United States), founded in 2017 by Paulo Rangel. It operates as a Developer of immunotherapies for treating cancer. Primmune Therapeutics has raised $60M in funding from investors like CAM Capital, Polaris Partners and Bioqube Ventures. The company has 337 active competitors, including 132 funded and 68 that have exited. Its top competitors include companies like Abcellera Biologics, Agios Pharmaceuticals and TScan Therapeutics.

Company Details

Primmune Therapeutics is developing immunotherapies for treating cancer. They are developing a small molecule (orally administered) which is a toll-like receptor 7 (TLR7) agonist (an endosomal innate immune sensor capable of detecting single-stranded ribonucleic acid) helps in systemic activation of innate immunity. It gets expressed on plasmacytoid dendritic cells.

Website: www.primmunerx.com/
Social
Email ID: *****@primmunerx.com

Key Metrics

Founded Year

2017

Location

San Diego, United States

Stage

Series B

Total Funding

$60M in 8 rounds

Latest Funding Round

Series B, Jan 26, 2026, $*****

Investors

CAM Capital & 9 more

Ranked

14^th among 337 active competitors

Employee Count

9 as on Jun 30, 2026

Similar Companies

Abcellera Biologics & 437 more

View Primmune Therapeutics' full profile

Primmune Therapeutics has raised a total funding of $60M over 8 rounds. Its first funding round was on Oct 18, 2017. Its latest funding round was a Series B round on Jan 26, 2026 for $*****. 3 investors participated in its latest round. Primmune Therapeutics has 9 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Primmune Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 26, 2026	2920207	Series B	2766701	5545465	9896005	2554499
Nov 04, 2021	1915730	Series A	8936541	2226542	9317934	9681965
Jan 12, 2021	5572402	Series A	7450758	9034386	Bioqube Ventures	2412461

Access funding benchmarks and valuations. Sign up today!

View details of Primmune Therapeutics's funding rounds and investors

The founders of Primmune Therapeutics is Paulo Rangel. Charles Charlie Mcdermott is the CEO of Primmune Therapeutics.

Here are the details of Primmune Therapeutics' key team members:

Paulo Rangel: Co-Founder & CBO of Primmune Therapeutics.
Contact Info: 1 email address

View details of Primmune Therapeutics's Founder profiles and Board Members

Primmune Therapeutics' employee count trend

Primmune Therapeutics has 9 employees as of Jun 26. Here is Primmune Therapeutics's employee count trend over the years:

Employee count trend for Primmune Therapeutics

Uncover Primmune Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Primmune Therapeutics include Abcellera Biologics, Agios Pharmaceuticals and TScan Therapeutics. Here is the list of Top 10 competitors of Primmune Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	71/100
2nd	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	70/100
3rd	TScan Therapeutics 1995, Boston (United States), Public	Developer of T cell therapies to harness the immune system against cancer	$180M	BlackRock, RA Capital Management & 9 others	70/100
4th	Beijing Jiakesi drug development 2015, Beijing (China), Public	Developer of small molecule based therapeutics for cancer treatment	$55M	Qiming Venture Partners, Lilly Asia Ventures ... & 3 others	66/100
5th	Boundless Bio 2018, San Diego (United States), Public	Developer of therapeutics for cancer by targeting ecDNA	$252M	RA Capital Management, Nextech Invest & 19 others	65/100
6th	Lyell Immunopharma 2018, San Francisco (United States), Public	Developer of CAR- T therapy for cancer treatment	$493M	Sahsen Ventures, GSK & 5 others	63/100
7th	ABL Bio 2016, Seongnam-si (South Korea), Public	Bi-specific antibodies and Antibody-drug Conjugate immunotherapies for oncology and neurodegenerative diseases	$65M	QUAD, Hana Financial Group & 7 others	63/100
8th	Inotrem 2013, Paris (France), Series B	Developer of peptide immunotherapies for treating septic shock and acute myocardial infarction	$122M	Morningside, Morningside & 11 others	62/100
9th	Cumulus Oncology 2017, Edinburgh (United Kingdom), Seed	Developer of therapies for treating cancers	$19.2M	Eos Advisory, Scottish Investment Bank & 26 others	61/100
10th	Black Diamond Therapeutics 2017, Cambridge (United States), Public	Developing MasterKey therapies to defeat cancer resistance and improve patient lives	$207M	New Enterprise Associates, Boxer Capital ... & 19 others	61/100
14th	Primmune Therapeutics 2017, San Diego (United States), Series B	Developer of immunotherapies for treating cancer	$60M	Oberland Capital, CAM Capital & 8 others	60/100